AGC Biologics vs Catalent (Novo Holdings): CDMO Comparison
Side-by-side comparison of AGC Biologics and Catalent (Novo Holdings) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- AGC Biologics holds 23 active EMA GMP certificates; Catalent (Novo Holdings) does not appear in EudraGMDP.
On a 13-modality CDMO landscape, both AGC Biologics and Catalent (Novo Holdings) qualify as AAV manufacturers; AGC Biologics carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both AGC Biologics and Catalent (Novo Holdings) qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: AGC Biologics vs Catalent (Novo Holdings)
Which has the stronger FDA inspection record, AGC Biologics or Catalent (Novo Holdings)?
Both AGC Biologics and Catalent (Novo Holdings) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. AGC Biologics has 1 FDA inspection on record; Catalent (Novo Holdings) has 1.
How do AGC Biologics and Catalent (Novo Holdings) compare on European GMP coverage?
AGC Biologics holds 23 active EMA GMP certificates and 0 MHRA / UK certificates. Catalent (Novo Holdings) holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — AGC Biologics or Catalent (Novo Holdings)?
AGC Biologics is matched to 2 ClinicalTrials.gov records as a manufacturing partner; Catalent (Novo Holdings) is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for AAV manufacturing — AGC Biologics or Catalent (Novo Holdings)?
Both AGC Biologics and Catalent (Novo Holdings) are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
AGC Biologics carries a Signal Score of 81/100 and Catalent (Novo Holdings) carries 75/100 — a small lead for AGC Biologics. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →